HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line

Safely study the SARS-CoV-2 nucleocapsid protein with our ready-to-use HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line.
  • Leverage SBI's robust lentivector expression technology to study the SARS-CoV-2 nucleocapsid protein
  • Ready-to-use stable cell line accelerates your SARS-CoV-2 studies
  • The overexpression lentivector is also available as plasmid and pre-packaged virus

Products

Catalog Number Description Size Price Quantity Add to Cart
CVD19-220A-1 HEK293 “N” SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line 2 x 10^6 Cells $3457
- +

Overview

Overview

Advance your COVID-19 studies with SBI

Explore interactions of the SARS-CoV-2 nucleocapsid protein with host proteins and more using the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line. Built using our SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, this stable cell line overexpresses the SARS-CoV-2 "N" protein—the nucleocapsid—from the CMV promoter, with a separate EF1α promoter driving expression of the puromycin resistance gene for selection.
  • Leverage SBI's robust lentivector expression technology to study the SARS-CoV-2 nucleocapsid protein
  • Ready-to-use stable cell line accelerates your SARS-CoV-2 studies
  • The overexpression lentivector is also available as plasmid and pre-packaged virus
  See all of our COVID-19-related Expression Constructs
Catalog NumberProduct name
CVD19-100PA/VA-1ACE2 Expression Lentivector, pCDH-CMV-ACE2-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-140PA/VA-1NRP1 Expression Lentivector, pCDH-CMV-NRP1-EF1α-Neo (Plasmid or Pre-packaged Lentivirus)
CVD19-120PA/VA-1SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, pCDH-CMV-SARS-CoV-2-N-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-130PA/VA-1SARS-CoV-2 Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-S-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-135PA/VA-1SARS-CoV-2 Humanized Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-hS-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-200A-1HEK293 ACE2 Stable Cell Line
CVD19-260A-1HEK293-ACE2-NRP1 Overexpression Stable Cell Line
CVD19-220A-1HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line
CVD19-420A-1
CVD19-425A-1
"N" SARS-CoV-2 Nucleocapsid mRNA
CVD19-430A-1
CVD19-435A-1
"S" SARS-CoV-2 Spike Glycoprotein mRNA
CVD19-440A-1
CVD19-445A-1
"S" SARS-CoV-2 Spike Omicron mRNA

How It Works

Supporting Data

Supporting Data

Figure 1. The SARS-CoV-2 nucleocapsid protein is well expressed in the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line. We transduced the SARS-CoV-2 Nucleocapsid Overexpression Lentivector (pCDH-CMV-SARS-CoV-2-N-EF1α-Puro) into HEK293 cells to create the stable cell line. To demonstrate the robust expression of the nucleocapsid protein in this cell line, we extracted total protein and analyzed nucleocapsid protein expression via western blot. The parental HEK293 cells display no nucleocapsid expression whereas the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line possesses robust nucleocapsid expression.

FAQs

Resources

We're sorry, an error has occurred while generating this content.

Citations

HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line $3,457.00

Products

Catalog Number Description Size Price Quantity Add to Cart
CVD19-220A-1 HEK293 “N” SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line 2 x 10^6 Cells $3457
- +

Overview

Overview

Advance your COVID-19 studies with SBI

Explore interactions of the SARS-CoV-2 nucleocapsid protein with host proteins and more using the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line. Built using our SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, this stable cell line overexpresses the SARS-CoV-2 "N" protein—the nucleocapsid—from the CMV promoter, with a separate EF1α promoter driving expression of the puromycin resistance gene for selection.
  • Leverage SBI's robust lentivector expression technology to study the SARS-CoV-2 nucleocapsid protein
  • Ready-to-use stable cell line accelerates your SARS-CoV-2 studies
  • The overexpression lentivector is also available as plasmid and pre-packaged virus
  See all of our COVID-19-related Expression Constructs
Catalog NumberProduct name
CVD19-100PA/VA-1ACE2 Expression Lentivector, pCDH-CMV-ACE2-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-140PA/VA-1NRP1 Expression Lentivector, pCDH-CMV-NRP1-EF1α-Neo (Plasmid or Pre-packaged Lentivirus)
CVD19-120PA/VA-1SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, pCDH-CMV-SARS-CoV-2-N-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-130PA/VA-1SARS-CoV-2 Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-S-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-135PA/VA-1SARS-CoV-2 Humanized Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-hS-EF1α-Puro (Plasmid or Pre-packaged Lentivirus)
CVD19-200A-1HEK293 ACE2 Stable Cell Line
CVD19-260A-1HEK293-ACE2-NRP1 Overexpression Stable Cell Line
CVD19-220A-1HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line
CVD19-420A-1
CVD19-425A-1
"N" SARS-CoV-2 Nucleocapsid mRNA
CVD19-430A-1
CVD19-435A-1
"S" SARS-CoV-2 Spike Glycoprotein mRNA
CVD19-440A-1
CVD19-445A-1
"S" SARS-CoV-2 Spike Omicron mRNA

How It Works

Supporting Data

Supporting Data

Figure 1. The SARS-CoV-2 nucleocapsid protein is well expressed in the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line. We transduced the SARS-CoV-2 Nucleocapsid Overexpression Lentivector (pCDH-CMV-SARS-CoV-2-N-EF1α-Puro) into HEK293 cells to create the stable cell line. To demonstrate the robust expression of the nucleocapsid protein in this cell line, we extracted total protein and analyzed nucleocapsid protein expression via western blot. The parental HEK293 cells display no nucleocapsid expression whereas the HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line possesses robust nucleocapsid expression.

FAQs

Resources

We're sorry, an error has occurred while generating this content.

Citations